PMID- 37883084 OWN - NLM STAT- MEDLINE DCOM- 20231027 LR - 20231029 IS - 2574-3805 (Electronic) IS - 2574-3805 (Linking) VI - 6 IP - 10 DP - 2023 Oct 2 TI - Ceftriaxone and the Risk of Ventricular Arrhythmia, Cardiac Arrest, and Death Among Patients Receiving Lansoprazole. PG - e2339893 LID - 10.1001/jamanetworkopen.2023.39893 [doi] LID - e2339893 AB - IMPORTANCE: The combination of ceftriaxone and lansoprazole has been shown to prolong the corrected QT interval on electrocardiogram. However, it is unknown whether this translates to clinically important patient outcomes. OBJECTIVE: To compare lansoprazole with another proton pump inhibitor (PPI) during ceftriaxone treatment in terms of risk for ventricular arrhythmia, cardiac arrest, and in-hospital mortality. DESIGN, SETTING, AND PARTICIPANTS: A retrospective cohort study including adult medical inpatients receiving ceftriaxone with lansoprazole or another PPI in 13 hospitals in Ontario, Canada, was conducted from January 1, 2015, to December 31, 2021. EXPOSURE: Lansoprazole during ceftriaxone treatment vs other PPIs during ceftriaxone treatment. MAIN OUTCOMES AND MEASURES: The primary outcome was a composite of ventricular arrhythmia or cardiac arrest that occurred after hospital admission. The secondary outcome was all-cause in-hospital mortality. Propensity-score weighting was used to adjust for covariates including hospital site, demographic characteristics, comorbidities, risk factors for ventricular arrhythmia, illness severity, admitting diagnoses, and concomitant medications. RESULTS: Of the 31 152 patients hospitalized on internal medicine wards who were treated with ceftriaxone while receiving a PPI, 16 135 patients (51.8%) were male, and the mean (SD) age was 71.7 (16.0) years. The study included 3747 patients in the lansoprazole group and 27 405 patients in the other PPI group. Ventricular arrhythmia or cardiac arrest occurred in 126 patients (3.4%) within the lansoprazole group and 319 patients (1.2%) within the other PPI group. In-hospital mortality occurred in 746 patients (19.9%) within the lansoprazole group and 2762 patients (10.1%) in the other PPI group. After weighting using propensity scores, the adjusted risk difference for the lansoprazole group minus other PPI group was 1.7% (95% CI, 1.1%-2.3%) for ventricular arrhythmia or cardiac arrest and 7.4% (95% CI, 6.1%-8.8%) for in-hospital mortality. CONCLUSIONS AND RELEVANCE: The findings of this cohort study suggest that combination therapy with lansoprazole and ceftriaxone should be avoided. More studies are needed to determine whether these findings could be replicated in other populations and settings. FAU - Bai, Anthony D AU - Bai AD AD - Division of Infectious Diseases, Department of Medicine, Queen's University, Kingston, Ontario, Canada. AD - Department of Health Research Methods, Evidence and Impact, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada. FAU - Wilkinson, Amelia AU - Wilkinson A AD - Division of General Internal Medicine, Department of Medicine, Queen's University, Kingston, Ontario, Canada. FAU - Almufleh, Aws AU - Almufleh A AD - Division of Cardiology, Department of Medicine, Queen's University, Kingston, Ontario, Canada. FAU - Rai, Mandip AU - Rai M AD - Division of Gastroenterology, Department of Medicine, Queen's University, Kingston, Ontario, Canada. FAU - Razak, Fahad AU - Razak F AD - Department of Medicine, University of Toronto, Toronto, Ontario, Canada. AD - Li Ka Shing Knowledge Institute, St Michael's Hospital, Unity Health Toronto, Toronto, Ontario, Canada. AD - Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada. FAU - Verma, Amol A AU - Verma AA AD - Department of Medicine, University of Toronto, Toronto, Ontario, Canada. AD - Li Ka Shing Knowledge Institute, St Michael's Hospital, Unity Health Toronto, Toronto, Ontario, Canada. AD - Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada. FAU - Srivastava, Siddhartha AU - Srivastava S AD - Division of General Internal Medicine, Department of Medicine, Queen's University, Kingston, Ontario, Canada. LA - eng GR - CIHR/Canada PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20231002 PL - United States TA - JAMA Netw Open JT - JAMA network open JID - 101729235 RN - 0K5C5T2QPG (Lansoprazole) RN - 75J73V1629 (Ceftriaxone) RN - 0 (Proton Pump Inhibitors) SB - IM MH - Adult MH - Humans MH - Male MH - Aged MH - Female MH - Lansoprazole/therapeutic use MH - *Ceftriaxone/adverse effects MH - Cohort Studies MH - Retrospective Studies MH - Arrhythmias, Cardiac/chemically induced/epidemiology MH - *Heart Arrest/chemically induced/epidemiology MH - Proton Pump Inhibitors/adverse effects MH - Inpatients MH - Ontario/epidemiology PMC - PMC10603497 COIS- Conflict of Interest Disclosures: Dr Razak reported receiving a salary award from the Canada Research Chairs Program and is a part time salaried employee of Ontario Health. Dr Verma reported receiving personal fees from Ontario Health as a part-time employee and grants from the University of Toronto Temerty Professorship of AI Research and Education in Medicine outside the submitted work. No other disclosures were reported. EDAT- 2023/10/26 12:42 MHDA- 2023/10/27 06:43 PMCR- 2023/10/26 CRDT- 2023/10/26 11:33 PHST- 2023/10/27 06:43 [medline] PHST- 2023/10/26 12:42 [pubmed] PHST- 2023/10/26 11:33 [entrez] PHST- 2023/10/26 00:00 [pmc-release] AID - 2811108 [pii] AID - zoi231164 [pii] AID - 10.1001/jamanetworkopen.2023.39893 [doi] PST - epublish SO - JAMA Netw Open. 2023 Oct 2;6(10):e2339893. doi: 10.1001/jamanetworkopen.2023.39893.